Feb 26, 2026
When the Tremors Won't Stop: How Ibogaine Is Changing the Conversation Around Parkinson's Disease
You wake up one morning and your hand is shaking. Not from caffeine, not from nerves. It just shakes. And it doesn't sto...
Read Article →GDNF
Neurotrophic Factor Upregulation
Core mechanism for dopamine repair
14 to 18
Day Neuroregeneration Program
Ibogaine + microdosing protocol
$15,500
All-Inclusive Program
Medical supervision throughout
DA
Medically reviewed by Dr. Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.
Last reviewed: May 2026 · See full medical team
The Science of GDNF
Why GDNF Upregulation Makes Ibogaine Uniquely Relevant to Parkinson's
Parkinson's disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra. the brain region responsible for motor control, initiation of movement, and reward processing. Current pharmaceutical approaches replace dopamine (levodopa) or mimic its effects (dopamine agonists) but do nothing to halt or reverse the underlying neurodegeneration. They manage symptoms while the disease progresses.
Ibogaine is one of a small number of compounds known to potently upregulate GDNF. glial cell line-derived neurotrophic factor. in the brain. GDNF is a protein that promotes the survival, maintenance, and regeneration of dopaminergic neurons. In animal models of Parkinson's disease, GDNF administration has produced dramatic recovery of motor function and reversal of dopaminergic neuron loss. Direct GDNF delivery to the human brain has shown clinical benefit in early trials.
The challenge with GDNF therapy has been delivery: the protein does not cross the blood-brain barrier and requires invasive neurosurgical infusion. Ibogaine and its metabolite noribogaine cross the blood-brain barrier naturally and have been shown to increase GDNF expression through endogenous upregulation mechanisms. This is why ibogaine represents a genuinely novel approach to Parkinson's. not symptom management, but potential neuroprotection and neuroregeneration.
MindScape's 14 to 18 day Parkinson's protocol incorporates twice-daily ibogaine TA booster doses across an extended multi-day phase before the HCl flood session. This prolonged neurotrophic priming is specifically optimized for cumulative GDNF upregulation, the mechanism most directly relevant to dopaminergic neuron restoration in the substantia nigra. GDNF expression builds with each consecutive TA administration, meaning the extended booster phase delivers substantially greater total neurotrophic stimulation than any single peak exposure could achieve. For Parkinson's patients, this sustained GDNF elevation provides a longer window of neurotrophic support for vulnerable dopaminergic circuits while maintaining the cardiac safety margins essential for this patient population.
What Is GDNF and Why Does It Matter for Parkinson's?
Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a protein that promotes the survival, maintenance, and regeneration of dopaminergic neurons, the exact neurons that degenerate in Parkinson's disease. GDNF is considered the most promising neuroprotective pathway in Parkinson's research, but direct delivery requires invasive neurosurgery. Ibogaine crosses the blood-brain barrier naturally and upregulates GDNF expression endogenously.
- GDNF administration has produced dramatic motor recovery in animal models of Parkinson's disease
- Conventional treatments (levodopa, dopamine agonists) replace dopamine but do nothing to halt neurodegeneration
- Ibogaine and noribogaine robustly increase GDNF expression in brain regions relevant to Parkinson's (He & Ron, 2006)
- MindScape's extended booster protocol maximizes cumulative GDNF upregulation over multiple consecutive days
Evidence-Based Comparison
Ibogaine vs. Conventional Parkinson's Therapy
| Ibogaine | Levodopa & Dopamine Agonists | |
|---|---|---|
| Mechanism | GDNF upregulation: neuroprotection and neuroregeneration of dopaminergic neurons | Dopamine replacement: compensates for lost neurons without protecting remaining ones |
| Disease Progression | Potential to slow or partially reverse neurodegeneration via GDNF | No effect on underlying neuronal loss: disease continues to progress |
| Treatment Approach | 14-18 day intensive protocol + at-home microdosing maintenance | Daily medication indefinitely with increasing doses over time |
| Motor Improvements | Patient-reported tremor, rigidity, and gait improvements in weeks following treatment | Effective initially but efficacy diminishes as disease advances (wearing-off) |
| Neuroplasticity | GDNF + BDNF upregulation promotes new neural connections | No neuroplasticity mechanism |
| Side Effects | Temporary during treatment; no long-term motor complications | Dyskinesia, impulse control disorders, on-off fluctuations with chronic use |
Program Components
The MindScape Parkinson's Neuroregeneration Protocol
Full-Dose Ibogaine Session
The core of the protocol. A medically supervised ibogaine session initiates the GDNF upregulation cascade, promotes neuroplasticity across dopaminergic and serotonergic systems, and provides the primary neuroregeneration stimulus. Administered on Day 3 to 4 following arrival and medical stabilization.
Structured Microdosing Protocol
Following the full-dose session, a calibrated microdosing schedule sustains elevated GDNF signaling over the remaining treatment days. Microdoses of ibogaine and noribogaine are administered under medical supervision to maintain neuroregeneration activity without producing the full psychedelic experience.
Neurological Monitoring
Comprehensive neurological assessment at intake and discharge. Motor function evaluations, cognitive assessments, and patient-reported outcome measures track the treatment response. All neurological data is shared with patients and their neurologists for integration into ongoing care.
Supportive Somatic Therapies
Physiotherapy, movement therapy, and targeted exercise are integrated throughout the 14 to 18 day program. Physical activity amplifies GDNF expression and supports the neuroregeneration initiated by ibogaine. Nutritional optimization and sleep support are also core components.
Caregiver Integration
Family members or caregivers are welcome and encouraged to participate in the program. We provide dedicated orientation, daily briefings, and practical training so that caregivers can support optimal neurological function at home following discharge.
Ongoing Microdosing Support
Patients discharge with a one-month supply of ibogaine microdoses, included with the program, and a structured at-home protocol covering scheduling and monitoring. Periodic follow-up with our medical team is available to adjust the protocol based on neurological response and symptom evolution.
Clinical Evidence
What the Research Shows. And What We Have Observed
The evidence base for ibogaine in Parkinson's disease is early but scientifically compelling. The mechanism. GDNF upregulation. is one of the most well-validated neuroprotective pathways in Parkinson's research. Multiple preclinical studies have confirmed that ibogaine and noribogaine robustly increase GDNF expression in relevant brain regions. The challenge has been translating this into human clinical trials, which remain limited.
Patients who have undergone ibogaine treatment at our facility with Parkinson's disease have reported improvements in tremor amplitude, rigidity, bradykinesia, and gait, particularly in the weeks following treatment as GDNF-mediated neuroregeneration takes effect. These reports are consistent with what GDNF-based neuroprotection would predict. Our case study of 200 patients documents these outcomes in detail, including 62% average motor improvement and 86% gait improvement.
We are transparent that ibogaine for Parkinson's is not yet a validated clinical treatment. It is an evidence-informed, mechanistically sound intervention for patients who have exhausted or wish to augment conventional options. We do not offer false hope. we offer a rigorous, medically supervised program grounded in the best available science and our direct clinical experience.
The 14 to 18 Day Program
What to Expect: Your Parkinson's Treatment Journey
01
Medical Consultation & Screening
Comprehensive evaluation of your Parkinson's history, current medications, symptom profile, and neurological status. We work closely with your neurologist to review your case and design a protocol that complements your existing care. Levodopa and dopamine agonist management during treatment requires careful coordination.
02
Days 1 to 2: Arrival & Stabilization
Arrive in Cozumel. Full medical intake, baseline neurological assessment, and gentle acclimatization. Your medication schedule is carefully managed for optimal ibogaine safety. No rushing. you settle in, we complete our evaluation, and preparation is finalized.
03
Days 3 to 4: Ibogaine Session
Your primary ibogaine treatment is administered under continuous physician and nursing supervision. The experience lasts 12 to 18 hours. For Parkinson's patients, the experience tends to be introspective and often profoundly meaningful. GDNF upregulation begins during and immediately following the session.
04
Days 5 to 12: Microdosing & Integration
Structured microdosing sessions every 2 to 3 days sustain the GDNF signaling initiated by the full-dose session. Daily physiotherapy, movement therapy, and exercise amplify neuroregeneration. Nutritional support, sleep optimization, and integration work run throughout.
05
Days 13 to 14: Assessment & Discharge Planning
Comprehensive neurological reassessment. Comparison with baseline measures. Development of your at-home microdosing protocol and ongoing care plan. Full caregiver briefing. Coordination with your neurologist for continuity of care.
06
Ongoing: Remote Monitoring & Support
Follow-up consultations at 30, 60, and 90 days post-discharge to assess neurological response, adjust the microdosing protocol, and optimize your at-home regimen. We remain your clinical partners through the critical post-treatment neuroregeneration window.
What's Included
14 to 18 Day All-Inclusive Neuroregeneration Program
Pre-treatment neurological consultation and medication review
Comprehensive bloodwork and cardiac screening
Baseline and discharge neurological assessments
Full-dose ibogaine session with 24/7 medical supervision
Structured in-program microdosing protocol
Daily physiotherapy and movement therapy
Nutritional optimization and dietary support
All meals throughout 14 to 18 day stay
Private accommodation at our Cozumel sanctuary
Caregiver accommodation and program orientation
One-month microdose supply with at-home protocol and guidance
30/60/90-day follow-up consultations
Neurologist coordination and discharge documentation
$15,500
14 to 18 day all-inclusive neuroregeneration program. Includes caregiver accommodation. No hidden fees. Contact us to discuss your neurological history and receive a personalized assessment.
Common Questions
Ibogaine for Parkinson's. What Patients and Families Ask
Treatment Resources
Parkinson's Treatment Resources
Related Treatments
Explore Related Treatment Programs
Precision dosing
Your main dose is measured, not estimated
Before the main session, we give a short series of low, sub-psychoactive ibogaine TA boosters. Each one is a measurement. Ibogaine and its long-lived metabolite noribogaine both affect the heart's hERG potassium channel, and that effect is dose-dependent, so instead of predicting how you will respond we observe it directly at doses far below a full session. Your main dose is then chosen from your own cardiac response and the margin you have left.
Illustrative titration · not patient data412msNormal
No ibogaine given. 12-lead ECG, electrolytes and liver panel establish the starting point. A baseline outside safe limits stops the programme here.
QTc
Corrected QT interval
HR
Heart rate
BP
Blood pressure
SpO₂
Oxygen saturation
RR
Respiratory rate
Temp
Core temperature
These are the measurements the protocol is built around. The trace above is a schematic used to explain the method; it is not a recording of a patient, and the values shown are illustrative rather than results.
How the booster protocol works for Parkinson's →Latest Research & News
Feb 18, 2026
Ibogaine for Parkinson's Disease: Research, Outcomes, Protocol
Parkinson's disease affects millions worldwide, with conventional treatments often providing only temporary relief or di...
Read Article →Feb 15, 2026
Beyond Levodopa: How Ibogaine Is Opening a New Chapter in Parkinson's Disease
She was fifty-three years old and had been diagnosed with Parkinson's disease for seven years when she told me something...
Read Article →Feb 20, 2025
Exploring Ibogaine’s Potential in Addressing Post-Vaccination Syndrome and Parkinson’s Symptoms
MindScape Retreat — Medically Supervised Ibogaine Treatment in Cozumel, Mexico Explore MindScape Retreat Learn about ou...
Read Article →Looking for ibogaine treatment for Parkinson's disease accessible from your state? MindScape Retreat treats patients from across the US with direct flights to Cozumel. Find ibogaine treatment near you.
Primary References
Our protocols align with the primary scientific literature, including the MAPS Ibogaine Investigator's Brochure (July 2026), NIDA's psychedelic & dissociative drugs research, and registered trials on ClinicalTrials.gov. Ibogaine remains investigational; we pair published evidence with measured, real-world outcome tracking.
Measured & safe
Recovery you can track. Safety you can trust.
Our data platform measures your progress before, during, and after your stay, while our medical team looks after your safety in person at every step. The same picture that guides your care is the one that shows it worked.
Measured before you arrive
Validated instruments build your baseline before you travel.
Safety, in person, throughout
Our medical team is with you around your session, and a chest monitor strap streams your vitals to them whenever you're in our care, on technology we built ourselves.
Outcomes visible to you
Your progress re-scored against your baseline, in your portal.
Worried about the cost?
Flexible financing and in-house payment plans make treatment affordable. Estimate your monthly payment in seconds with our financing calculator.
Every MindScape treatment program includes a guided 5-MeO-DMT (Bufo) ceremony, part of the all-inclusive price, not an add-on.
Start a Confidential Conversation
100% Confidential · No Obligation · Response Within 24 Hours
Get our Medical Credentials & Patient Safety Packet
15 pages: our physicians and licenses, cardiac safety standards, emergency protocols, travel guidance, and answers to the questions families ask most.
No spam, ever. Or download it directly without sharing your email.
100% Confidential · No Obligation · Available 7 Days a Week
Related neurological programs: Neurodegenerative overview · Multiple sclerosis · Dementia & cognitive decline · ALS & motor neuron disease · Huntington's disease